NTLA vs. CLDX, MYGN, NEOG, QDEL, EDIT, CLLS, SGMO, LNTH, BEAM, and PRVA
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), Neogen (NEOG), QuidelOrtho (QDEL), Editas Medicine (EDIT), Cellectis (CLLS), Sangamo Therapeutics (SGMO), Lantheus (LNTH), Beam Therapeutics (BEAM), and Privia Health Group (PRVA). These companies are all part of the "medical" sector.
Intellia Therapeutics (NASDAQ:NTLA) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Celldex Therapeutics received 180 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 74.84% of users gave Celldex Therapeutics an outperform vote while only 69.55% of users gave Intellia Therapeutics an outperform vote.
Intellia Therapeutics currently has a consensus target price of $67.00, indicating a potential upside of 227.79%. Celldex Therapeutics has a consensus target price of $66.00, indicating a potential upside of 82.83%. Given Intellia Therapeutics' higher probable upside, research analysts plainly believe Intellia Therapeutics is more favorable than Celldex Therapeutics.
Intellia Therapeutics has a net margin of -893.34% compared to Celldex Therapeutics' net margin of -2,054.46%. Celldex Therapeutics' return on equity of -41.06% beat Intellia Therapeutics' return on equity.
88.8% of Intellia Therapeutics shares are held by institutional investors. 3.0% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.7% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Intellia Therapeutics had 5 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Intellia Therapeutics and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.24 beat Intellia Therapeutics' score of 0.14 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Celldex Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Intellia Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
Summary
Intellia Therapeutics and Celldex Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Intellia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
